Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
AMLX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
businesswire.com
less than 1 hour ago
reuters.com
7 hours ago
businesswire.com
16 hours ago
seekingalpha.com
18 hours ago
Quote Panel
Key Metrics
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
NASDAQ
Unprofitable
Unprofitable
0.11Ā ( 0.93%)
Pre-market 11.83$
-0.13 (-1.09%)
Relative Strenght
96
Volume Buzz
-27%
Earning Acce
No
Dist 52w H.
2%Forecast
2026-Revenue
-208%2026-EPS
100%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
21.00(75.59%)
Number of analyst
2
Last analyst upgrade/downgrade
Jefferies
initialisePrevious: Not converted
2025-06-24
Now: Hold
Guggenheim
initialisePrevious: Not converted
2025-06-24
Now: Buy
UBS
initialisePrevious: Not converted
2025-06-24
Now: Neutral
Bank of America Securities
upgradePrevious: Not converted
2024-10-23
Now: Buy
Relative Strength
AMLX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Earnings Growth
YoY
Current
Estimates
Q3.23
+133%
0.3
vsĀ -0.92
Q4.23
+111%
0.07
vsĀ -0.65
Q1.24
N/A
-0.46
vsĀ 0.02
Q2.24
N/A
-0.73
vsĀ 0.31
Q3.24
N/A
-0.53
vsĀ 0.3
Q4.24
N/A
-0.55
vsĀ 0.07
Q1.25
N/A
-0.42
vsĀ -0.46
Q2.25
N/A
-0.46
vsĀ -0.73
Q3.25
N/A
-0.46
vsĀ -0.53
Q4.25
N/A
-0.45
vsĀ -0.55
Sales Growth
YoY
Current
Estimates
Q3.23
+29666%
102.7MĀ vsĀ 345K
Q4.23
+396%
108.4MĀ vsĀ 21.9M
Q1.24
+24%
88.6MĀ vsĀ 71.4M
Q2.24
-101%
-1023000.00Ā vsĀ 98.2M
Q3.24
-100%
416KĀ vsĀ 102.7M
Q4.24
-101%
-665000.00Ā vsĀ 108.4M
Q1.25
-100%
NAĀ vsĀ 88.6M
Q2.25
+100%
NAĀ vsĀ -1023000
Q3.25
-87%
52KĀ vsĀ 416K
Q4.25
+92%
-52000.00Ā vsĀ -665000
Return on Equity
QoQ
Q1.23
+0%
0
vsĀ -0.13
Q2.23
+6%
0.06
vsĀ 0
Q3.23
+5%
0.05
vsĀ 0.06
Q4.23
+1%
0.01
vsĀ 0.05
Q1.24
-37%
-0.37
vsĀ 0.01
Q2.24
-28%
-0.28
vsĀ -0.37
Q3.24
-37%
-0.37
vsĀ -0.28
Q4.24
-23%
-0.23
vsĀ -0.37
Q1.25
-18%
-0.18
vsĀ -0.23
Q2.25
-25%
-0.25
vsĀ -0.18
Institutionnal Ownership
QoQ
Q1.23
164
164
vsĀ 149
10%
Q2.23
170
170
vsĀ 164
4%
Q3.23
189
189
vsĀ 170
11%
Q4.23
206
206
vsĀ 189
9%
Q1.24
177
177
vsĀ 206
-14%
Q2.24
128
128
vsĀ 177
-28%
Q3.24
116
116
vsĀ 128
-9%
Q4.24
132
132
vsĀ 116
14%
Q1.25
135
135
vsĀ 132
2%
Q2.25
126
126
vsĀ 135
-7%